Complete coverage on

Schering AG

Latest Stories

CNNMoney: Merck banks big on Schering savingsupdated: Mon Mar 09 2009 13:47:00

Merck has never believed in big pharma M&A. So why is it bidding $44 billion for rival Schering-Plough - which might lose the right to sell an important drug because of the deal?

CNNMoney: Stocks in rebound modeupdated: Mon Mar 09 2009 10:22:00

Stocks turned higher Monday morning as investors considered Merck's $41 billion purchase of Schering-Plough and opted to scoop up shares hit in the recent selloff. The Long Wait for Male Birth Controlupdated: Sun Aug 03 2008 20:30:00

Researchers say that hormonal birth control for men is as possible and safe as the Pill for women, but the pharmaceutical industry says there's no market

CNNMoney: Schering stock jumps on job cutsupdated: Thu Apr 03 2008 12:44:00

Schering-Plough's stock jumped Thursday, after the drugmaker's chief executive announced he would cut 10% of its staff.

CNNMoney: Schering stock jumps on earnings winupdated: Tue Feb 12 2008 12:00:00

Schering-Plough may have lost billions of dollars in the fourth quarter from an acquisition, but its stock jumped Tuesday as the drugmaker's earnings without charges beat expectations.

Fortune: Schering CEO in the hot seatupdated: Mon Feb 11 2008 14:00:00

As Schering-Plough unveils full-year financial results for 2007 tomorrow, CEO Fred Hassan is likely to be peppered with questions about how he managed a recently released study of embattled cholesterol drug, Vytorin.

Fortune: Cholesterol skeptics have their dayupdated: Wed Feb 06 2008 16:46:00

Is low cholesterol the pathway to a healthier heart? That's certainly what most medical experts - and their patients - have assumed for the last 30 years or so. But a recently-released study of Merck and Schering-Plough's cholesterol-lowering drug, Vytorin, is giving new voice to medical critics who have groused for decades about the questionable benefit of using medications to lower cholesterol and thereby prevent heart disease.

Can surgery cure diabetes?updated: Fri Jan 25 2008 17:08:00

CNN's Dr. Sanjay Gupta examines recent studies that show Type 2 diabetes could vanish after bariatric surgery.

CNNMoney: FDA scrutinizes Vytorinupdated: Fri Jan 25 2008 17:08:00

Government regulators said Friday they are analyzing recent study results regarding cholesterol drug Vytorin, but that it's too early to tell whether it will take any regulatory action.

CNNMoney: Schering stock nearly crawls out of its holeupdated: Wed Jan 16 2008 17:27:00

Schering-Plough's stock almost crawled out of its hole Wednesday after a two-day lashing sparked by the results of a cholesterol drug trial, but the shares fell just before the market's close.

Cholesterol drug in doubtupdated: Wed Jan 16 2008 17:27:00

A study suggests the cholesterol drug Vytorin may not help arteries more than a generic. CNN's Dr. Sanjay Gupta reports.

CNNMoney: Schering's potential anti-clotting blockbusterupdated: Wed Nov 07 2007 15:19:00

Recently announced safety problems with Eli Lilly & Co.'s prasugrel could mean good news for Schering-Plough and its experimental anti-clotting drug TRA, but it would be years before it could enter the market.

Fortune: Schering still strong after earnings missupdated: Tue Oct 23 2007 11:47:00

Things aren't as bad as they look at Schering-Plough. The company's shares fell more than 13% yesterday, after its third quarter earnings failed to match Wall Street's expectations. But the company's future, despite the investor sell-off, remains promising.

Stop snoring!updated: Tue Oct 02 2007 14:12:00

England's government is set to pay for pressurized air masks that combat sleep apnea. CNN's Alphonso Van Marsh reports.

CNNMoney: Schering pushing hard to diversifyupdated: Tue Oct 02 2007 14:12:00

Drugmaker Schering-Plough is a favorite of analysts and investors these days. It's no wonder: The company's flagship product, the cholesterol-fighting Vytorin, is breaking sales records and faces relatively little risk from cheaper generic versions from rivals.

CNNMoney: Street's bullish on Big Pharma earningsupdated: Mon Jul 16 2007 02:52:00

The Street is bullish on Big Pharma, and experts believe the launch of new, fast-growing drugs fueled earnings for most of the major U.S. drugmakers in the second quarter.

CNNMoney: Street divided over numbers from Big Pharmaupdated: Thu Apr 19 2007 10:30:00

The drugmakers Merck, Schering-Plough and Wyeth all reported strong first-quarter earnings - with Schering and Wyeth trouncing forecasts - but investor reaction was mixed.

CNNMoney: Stocks on the move Thursdayupdated: Thu Mar 15 2007 11:00:00

The following shares were among the most actively traded Thursday:

CNNMoney: Report: Schering ponders possible mergerupdated: Fri Sep 15 2006 08:04:00

The drug giant Schering-Plough is seriously considering approaching Bristol-Myers with a merger offer, according to a news report.

CNNMoney: Schering settles sales probe for $435 millionupdated: Tue Aug 29 2006 11:03:00

Schering-Plough said Tuesday it settled a criminal investigation into its sales practices and agreed to pay $435 million in fines and damages.

CNNMoney: Europe gains on lower oilupdated: Mon Oct 24 2005 09:39:00

European stocks edged higher on Monday, as oil prices below $60 a barrel and gains from drugmaker Schering gave a boost to markets.

Fortune: The dogged scientist, the old lab vial, and the QUEST TO STOP CANCERupdated: Mon Jun 27 2005 00:01:00

Do you enjoy delayed gratification? Consider a career in pharmaceutical research. The wait between a drug's discovery and its approval is usually well over a decade. Often it takes forever: Most ex...

CNNMoney: Stocks shrug off Fedupdated: Wed Feb 02 2005 09:39:00

Stocks finished higher for the third straight session Wednesday as investors yawned at the Fed's widely expected quarter-point rate hike.

CNNMoney: When will big pharma's time come?updated: Thu Jan 29 2004 10:24:00

Are the "big pharmas" finally ready to move up from the back of the pack?

Money Magazine: Funds: A knack for discoveryupdated: Thu Nov 06 2003 17:29:00

In an industry characterized by change, Samuel Isaly has been a rare constant.

Money Magazine: A Knack For Discovery Veteran fund manager Samuel Isaly of Eaton Vance Worldwide Health Sciences has a nose updated: Sat Nov 01 2003 00:01:00

In an industry characterized by change, Samuel Isaly has been a rare constant. Since becoming a drug analyst at age 23, after graduating from the London School of Economics, the manager of the $2 ...

Fortune: Is It Too Late To Save Schering? CEO Fred Hassan has a hair-raising task: fixing the drugmaker's problems in the updated: Mon Sep 15 2003 00:01:00

Fred Hassan talks like a professional therapist. Not in a cooing, I-feel-your-pain, Oprah sort of way, but with a gentle authority that, no matter how harsh the pronouncement, is still soothing. Sc...

Fortune: Bitter Medicine At Schering-Plough, chronic quality-control problems led to fines, sanctions, and a criminal probe.updated: Mon Oct 14 2002 00:01:00

Springtime on the plains of Midland, Texas, is an asthmatic's nightmare. Along with the tumbleweed and dust, there's always too much pollen floating in the wind. Alexis Milmine feels a stirring in ...

Fortune: Q&A: What Looks Hot at A.G. Edwards DOW 10,000? NOT SO SOONupdated: Mon Aug 03 1998 00:01:00

How does A.G. Edwards outdistance the S&P 500--and many bigger rivals? Stuart Freeman, the strategist who oversees Edwards' focus list, says the firm's St. Louis location probably helps: "We're les...

Money Magazine: The Nifty 50updated: Sat Aug 01 1998 00:01:00

Many of the blue-chip growth stocks known as the Nifty Fifty have outpaced the S&P 500, even if you measure from December 1972, when glamour stocks were near peak price/earnings ratios. The stocks ...

Fortune: PORTFOLIO TALK DRUGS AND BIOTECH: NEW HOPE FOR THE DEAD?updated: Mon Nov 29 1993 00:01:00

For almost two years, investors have quarantined pharmaceuticals and biotechnology stocks. From a peak in early 1992, both groups are down over 30%. The Medical Research Investment Fund has thrived...

Fortune: DRUG STOCKS: THE BEST ANTIDOTE TO RECESSION ANXIETYupdated: Mon Oct 08 1990 00:01:00

It's sweaty-palm season in the stock market. Inflation is rising, corporate earnings are disappointing, and the economy is anemic at best. As a result many investors are quietly shifting into defen...

We recommend